September 29, 2025

Uncategorized

New Releases from NCBI BookshelfUsing Research Networks to Compare Medicines for Autoimmune and Inflammatory Diseases – The Comparative Health Outcomes in Immune-mediated diseases CollaborativE (CHOICE) Study [Internet].​Using Research Networks to Compare Medicines for Autoimmune and Inflammatory Diseases – The Comparative Health Outcomes in Immune-mediated diseases CollaborativE (CHOICE) Study [Internet].

Leave a Comment / Uncategorized /

Individuals with autoimmune and inflammatory diseases who seek treatment face a rapidly changing and confusing landscape that includes multiple immunosuppressive […]

Uncategorized

New Releases from NCBI BookshelfQuizartinib (Vanflyta): Indication: In combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib maintenance monotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FMS-like tyrosine kinase 3 internal tandem duplication positive: Reimbursement Recommendation [Internet].​Quizartinib (Vanflyta): Indication: In combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib maintenance monotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FMS-like tyrosine kinase 3 internal tandem duplication positive: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

Canada’s Drug Agency (CDA-AMC) recommends that Vanflyta should be reimbursed by public drug plans for the treatment of adult patients

Uncategorized

New Releases from NCBI BookshelfDurvalumab (Imfinzi): Indication: As monotherapy, for the treatment of adult patients with limited-stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy: Reimbursement Recommendation [Internet].​Durvalumab (Imfinzi): Indication: As monotherapy, for the treatment of adult patients with limited-stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

Canada’s Drug Agency (CDA-AMC) recommends that Imfinzi be reimbursed by public drug plans for the treatment of adults with limited-stage

Uncategorized

New Releases from NCBI BookshelfDupilumab (Dupixent): Indication: Add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis inadequately controlled by systemic corticosteroids and/or surgery: Reimbursement Recommendation [Internet].​Dupilumab (Dupixent): Indication: Add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis inadequately controlled by systemic corticosteroids and/or surgery: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

Canada’s Drug Agency (CDA-AMC) recommends that Dupixent be reimbursed by public drug plans for the treatment of severe chronic rhinosinusitis

Uncategorized

New Releases from NCBI BookshelfDupilumab (Dupixent): Indication: For the treatment of adult patients with moderate-to-severe prurigo nodularis (PN) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids: Reimbursement Recommendation [Internet].​Dupilumab (Dupixent): Indication: For the treatment of adult patients with moderate-to-severe prurigo nodularis (PN) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

Canada’s Drug Agency (CDA-AMC) recommends that Dupixent be reimbursed by public drug plans for the treatment of adult patients with

Uncategorized

New Releases from NCBI BookshelfDoes a Community Education Program Help Increase Early Hospital Arrival and Ambulance Use for Patients Who Experience Stroke?—The CEERIAS Study [Internet].​Does a Community Education Program Help Increase Early Hospital Arrival and Ambulance Use for Patients Who Experience Stroke?—The CEERIAS Study [Internet].

Leave a Comment / Uncategorized /

Early hospital arrival after stroke onset increases access to proven treatments and improves outcomes. In addition to knowledge and recognition

Uncategorized

New Releases from NCBI BookshelfCrovalimab (Piasky): Indication: For the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults and adolescents 13 years of age and older with a body weight of at least 40 kg: Reimbursement Recommendation [Internet].​Crovalimab (Piasky): Indication: For the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults and adolescents 13 years of age and older with a body weight of at least 40 kg: Reimbursement Recommendation [Internet].

Leave a Comment / Uncategorized /

Canada’s Drug Agency (CDA-AMC) recommends that Piasky be reimbursed by public drug plans for the treatment of patients with paroxysmal

Useful Links

NEWREDMARS SKILL AND RESEARCH        FOUNDATION

Registration No: 771800548      Contact Number : +91-8249516996

©2021-2024. Newredmars Skill and Research Foundation. All Rights Reserved.

Scroll to Top